
Abiotrophia endocarditis: a case report and review of literature

Mevan Wijetunga MD*, Erlaine Bello MD**, Irwin Schatz MD***

Abstract

Nutritionally Variant Streptococci (NVS) were first grouped under viridans streptococci, although they differed from the latter by variant growth characteristics. NVS cause approximately 5% of cases of bacterial endocarditis. Infective endocarditis caused by NVS has a higher rate of complications than endocarditis caused by other viridans streptococci. Recently NVS were separated from other viridans streptococci to form a new genus Abiotrophia. Since then, only four case reports have described the clinical course of Abiotrophia endocarditis. Therefore, current knowledge on this disease derives from previous data on NVS endocarditis. We present the case of Abiotrophia endocarditis, followed by discussion of relevant literature.

Introduction

Nutritionally variant streptococci (NVS) were recently separated from other viridans streptococci to form a new genus *Abiotrophia*.¹ Since this taxonomic revision, only four case reports have described the clinical course *Abiotrophia* endocarditis.²⁻⁴ Therefore, current knowledge on this disease derives from previous data on NVS endocarditis. We present the case of *Abiotrophia* endocarditis, followed by discussion of relevant literature.

Case Report

A 31-year old male was admitted for a one-month history of malaise, night sweats, low-grade fever and palpitations. The patient denied previous rheumatic heart disease, IV drug use, recent dental, gastrointestinal or urogenital surgery. He recalled a heart murmur in his childhood. On physical examination he had painful nodules over the tips of his fingers, mild conjunctival pallor and a diastolic murmur at the left upper sternal border. Erythrocyte sedimentation rate was elevated at 55 mm/Hr. Echocardiography showed concentric left ventricular hypertrophy, moderate aortic insufficiency, left ventricular ejection fraction of 60% and a thickened aortic valve with a 2mm verrucous lesion on the right coronary cusp. Native valve endocarditis was suspected and the patient was started on intravenous ampicillin 2gm IV Q6hrs and gentamicin 70mg IV Q8hrs.

Blood cultures drawn on the day of admission did not reveal an initial growth. The patient was discharged home on day 4 of hospitalization. Upon discharge, the antibiotic regimen was changed to ceftriaxone 2gm IV Q24hrs and gentamicin 210mg IV Q24hrs. Ten days after his discharge, blood cultures showed fastidious growth of *Abiotrophia adiacens*, susceptible to ampicillin, ceftriaxone, chloramphenicol, clindamycin, erythromycin, penicillin and vancomycin. The patient completed a 4-week course of outpatient, intravenous antibiotic therapy with ceftriaxone and gentamicin.

The patient remained clinically stable during the next two months, until he developed symptoms of an upper respiratory tract infection. He was seen as an outpatient and was started on clarythromycin. During the ensuing week he noted progressive shortness of breath, orthopnea and paroxysmal nocturnal dyspnea. A chest roentgenogram documented bilateral diffuse lower lobe infiltrates. He was readmitted to the hospital.

The admission physical examination showed a well-developed man in mild respiratory distress at rest. His vital signs were: blood pressure 130/70, heart rate 127, respiratory rate 24 and temperature of 98.4. Jugular venous pressure was 7cm with hyperdynamic waveforms. His heart examination showed normal S1 and S2, a loud S4 and II/VI early decrescendo diastolic murmur over aortic region. Lung examination was significant for rales over lower 1/3 of lung fields. Hyperdynamic distal pulses were present. His extremities were without peripheral edema. An echocardiogram showed evidence of dilated cardiomyopathy, global impairment of left ventricular systolic function with an ejection fraction of 20-30% and aortic regurgitation. It was difficult to assess the extent of the valvular lesion. The patient underwent urgent cardiac catheterization, which documented 4+ aortic insufficiency, enlarged left ventricle with global hypokinesis and an estimated ejection fraction 20-30%.

Urgent aortic valve replacement surgery was performed with placement of St. Jude mechanical prosthesis. At the time of surgery, the patient was noted to have a congenital bicuspid aortic valve with partial fusion of commissures. The valve had areas of damage with approximately 1 cm perforations in both leaflets. There were areas of valvular thickening, but no vegetations were observed. The annulus was normal except for an area around the right coronary sinus where a localized pocket suggested a healed abscess.

Gram stain of valve tissue did not reveal white cells or organisms. Pathologic evaluation of the aortic valve documented fibrous valvulitis with focal granulation tissue consistent with acute and chronic inflammation. Aerobic and anerobic cultures of the aortic valve and blood cultures obtained at the time of presentation were sterile. The

Correspondence to:
Mevan Wijetunga MD
Department of Medicine
1356 Lusitana St., 7th Fl.
Honolulu, HI 96813
e-mail: mevan@hawaii.edu

patient was placed on intravenous levofloxacin and cefazolin. He had an uneventful recovery and was discharged on the day 8 of hospitalization.

Discussion

Nutritionally variant (deficient) streptococci (NVS) were originally described in 1961 by Frenkel and Hirsch as fastidious gram-positive bacteria that grew as satellite colonies around other bacterial species.⁵ NVS were first grouped under viridans streptococci, although they differed from the latter by variant growth characteristics. These organisms did not grow on blood or chocolate agar, but were shown to grow in complex media supplemented with L-cysteine or pyridoxine. Streaking blood agar with a gram positive organism such as *S. aureus*, or with gram negative organism or yeast were shown to provide NVS with the necessary nutrients that would allow the organism to grow as a halo of satellite colonies a phenomenon called microbial commensalism.^{6,7} Subsequently NVS were referred by a variety of names including "nutritionally deficient", "cell wall deficient", "thiol-requiring", "L-form", "satelliting" or "pyridoxine dependent streptococci".⁶

The taxonomic position of NVS remained unclear until 1989 when Bouvet et al. performed DNA-DNA hybridization studies and reclassified the NVS into *Streptococcus adjacens* and *Streptococcus defectives*.⁸ In 1995 Kawamura et al. determined the 16S rRNA sequences of these strains and transferred them to a new genus *Abiotrophia* as *A. adiacens* and *A. defectiva*.¹ This was followed by the description of other potential human pathogens within the same genus, *A. elegans* and *A. para-adiacens*.^{9,10} The term *Abiotrophia* indicated the innate nutritional deficiency of these organisms and their dependence on supplemental media for growth. Recently, another taxonomic revision has been proposed by Collins et al., as the genus *Abiotrophia* appear to have two distinct phyletic lineages. The reclassified genus has been named *Granulicatella*.¹¹

NVS are found in the normal flora of the oral cavity, upper respiratory, urogenital and gastrointestinal mucosa of humans.⁶ They have been recovered from blood, brain and pancreatic abscesses, oral ulcers, dental plaques, wound infections and urethral samples.^{6,12-17} NVS have also been isolated from patients with otitis externa, otitis media, conjunctivitis, endophthalmitis, infectious keratopathy, vertebral osteomyelitis, discitis, iatrogenic meningitis, post-partum sepsis and endocarditis.^{2,4-6,18-25} Given their fastidious growth rate and requirement of special microbiologic media, it is likely that the true incidence of NVS infections is underreported.

It is estimated that NVS cause approximately 5% of cases of bacterial endocarditis.⁶ Historically, NVS also accounted for cases of culture-negative endocarditis.²⁶ Most reported cases of NVS involve native valves while only a few cases involve prosthetic valves.^{2,6} Often, endocarditis occurs in the setting of previous valvular disease and is characterized by a slow, indolent course.^{25,27,28}

Present data suggest that infective endocarditis caused by NVS leads to a higher rate of complications than infections caused by other viridans streptococci. Comparison studies have shown a higher mortality rate (14% vs 5%), greater risk of embolization (33% vs. 11%), more congestive heart failure due to valvular insufficiency (33% vs. 18%) and increased rate of surgical intervention (33% vs.18%) when NVS is compared with other viridans

streptococci.²⁹ Treatment failure and relapse have been observed in 41% cases, as compared with 17% in other viridans streptococci.³⁰

A recent study showed that *A. adiacens* strains have a markedly high fibronectin binding capacity to extracellular matrix proteins, which may contribute to the high virulence of these organisms.³¹ They overproduce exopolysaccharide, which may play an additional protective role in the survival of the organism.²⁸ Moreover, *Abiotrophia* isolates have been shown to involve conjugative transposons in the dissemination of antibiotic resistance.³

In vitro studies have shown that when compared to most other viridans streptococci, NVS strains have moderate susceptibility and can develop tolerance to penicillin.^{7,30,32-34} Although high dose therapy has been recommended in certain circumstances, patients with NVS endocarditis may relapse after a full course of treatment despite in vitro high susceptibility to penicillin.^{6,35} NVS are generally susceptible to aminoglycosides and vancomycin.^{7,30,32,34} The synergistic combination of penicillin or vancomycin with an aminoglycoside has been shown to be more effective than penicillin alone.^{6,12,36} It is generally recommended that all patients with NVS endocarditis be treated with combination therapy for 4-6 weeks.³⁷

In a recent study of 39 isolates of *A. adiacens* and *A. defectiva*, the proportion of strains susceptible to penicillin were 55% and 8% respectively. In the same study, the susceptibilities for other antimicrobials were; amoxicillin 81% and 92%, ceftriaxone 63% and 83%, meropenem 96% and 100% respectively for the two strains. Both species showed 100% susceptibility to clindamycin, rifampin, levofloxacin, ofloxacin, quinupristin/dalfopristin and vancomycin.³⁴ Another recent study of 20 *Abiotrophia* isolates reported susceptibility to cefotaxime 65%, cefepime 47%, erythromycin 70%, clindamycin 95% and meropenem 90%.⁷ However, it should be noted that while NVS are susceptible to clindamycin, chloramphenicol and erythromycin, these antibiotics are not recommended for the treatment of NVS endocarditis.

Upon his second admission to the hospital, our patient did not show any evidence of on-going endocardial infection. The histopathology revealed sterile valves and repeated serum microbiology studies remained negative for infection. Hence, acute aortic regurgitation on his second admission was likely a non-infectious, delayed complication of abiotrophia endocarditis.

Abiotrophia endocarditis frequently has a high rate of complications. Long-term combination antibiotic therapy guided by susceptibility studies as well as clinical correlation, is necessary. High morbidity and mortality despite extended antibiotic therapy, is common. Abiotrophia endocarditis warrants regular follow up, despite apparent clinical recovery of the patient. Any change in clinical status, calls for close attention for early identification of complications or relapse.

Acknowledgements

Authors wish to thank Edward Shen, MD, Robert Hong, MD and James Ireland, MD at University of Hawaii Department of Medicine for their suggestions.

Authors


* Resident PGY-3, University of Hawaii Internal Medicine Residency Program, 1356 Lusitana Street 7th Floor, Honolulu, Hawaii 96813

** Assistant Professor, Chief, Division of Infectious Diseases, University of Hawaii Department of Medicine, 1356 Lusitana Street 7th Floor, Honolulu, Hawaii 96813

*** Professor of Medicine, University of Hawaii Department of Medicine, 1356 Lusitana Street 7th Floor, Honolulu, Hawaii 96813

References

1. Kawamura Y, Hou XG, Sultana F, Liu S, Yamamoto H, Ezaki T. Transfer of *Streptococcus adjacens* and *Streptococcus defectivus* to *Abiotrophia* gen. nov. as *Abiotrophia adiacens* comb. nov. and *Abiotrophia defectiva* comb. nov., respectively. *Int J Syst Bacteriol* 1995;45(4):798-803.
2. Christensen JJ, Gruhn N, Facklam RR. Endocarditis caused by *Abiotrophia* species. *Scand J Infect Dis* 1999;31(2):210-2.
3. Poyart C, Quesne G, Acar P, Berche P, Trieu-Cuot P. Characterization of the Tn916-like transposon Tn3872 in a strain of *abiotrophia defectiva* (*Streptococcus defectivus*) causing sequential episodes of endocarditis in a child. *Antimicrob Agents Chemother* 2000;44(3):790-3.
4. Verghese S, Mulasari A, Padmaja P, Mathew T, Elizabeth SJ, Chitra AK, et al. Bacterial endocarditis caused by *abiotrophia defectiva* (nutritionally variant streptococci). *Indian Heart J* 2000;52(5):594-6.
5. Frankel A, Hirsch W. Spontaneous development of L forms of *Streptococci* requiring secretions of other bacteria or sulphhydryl compounds for normal growth. *Nature* 1961;191:728-30.
6. Ruoff KL. Nutritionally variant streptococci. *Clin Microbiol Rev* 1991;4(2):184-90.
7. Murray CK, Walter EA, Crawford S, McEimeel ML, Jorgensen JH. *Abiotrophia* bacteremia in a patient with neutropenic fever and antimicrobial susceptibility testing of *abiotrophia* isolates. *Clin Infect Dis* 2001;32(10):E140-2.
8. Bouvet A, Grimont F, Grimont P. *Streptococcus defectivus* sp. nov. and *Streptococcus adiacens* sp. nov., nutritionally variant streptococci from human clinical specimens. *Int J Syst Bacteriol* 1989(39):290-94.
9. Roggenkamp A, Abele-Horn M, Trebesius KH, Tretter U, Autenrieth IB, Heesemann J. *Abiotrophia elegans* sp. nov., a possible pathogen in patients with culture-negative endocarditis. *J Clin Microbiol* 1998;36(1):100-4.
10. Kanamoto T, Sato S, Inoue M. Genetic heterogeneities and phenotypic characteristics of strains of the genus *Abiotrophia* and proposal of *Abiotrophia para-adiacens* sp. nov. *J Clin Microbiol* 2000;38(2):492-8.
11. Collins MD, Lawson PA. The genus *Abiotrophia* (Kawamura et al.) is not monophyletic: proposal of *Granulicatella* gen. nov., *Granulicatella adiacens* comb. nov., *Granulicatella elegans* comb. nov. and *Granulicatella balaenopterae* comb. nov. *Int J Syst Evol Microbiol* 2000;50 Pt 1:365-9.
12. Carey RB, Brause BD, Roberts RB. Antimicrobial therapy of vitamin B6-dependent streptococcal endocarditis. *Ann Intern Med* 1977;87(2):150-4.
13. Bottone E, Thomas C, Lindquist D, Janda J. Difficulties encountered in identification of a nutritionally deficient *Streptococcus* on the basis of its failure to revert to streptococcal morphology. *J Clin Microbiol* 1995;33:1022-24.
14. Biermann C, Fries G, Jehnichen P, Bhakdi S, Husmann M. Isolation of *Abiotrophia adiacens* from a brain abscess which developed in a patient after neurosurgery. *J Clin Microbiol* 1999;37(3):769-71.
15. Mikkelsen L, Theilade E, Poulsen K. *Abiotrophia* species in early dental plaque. *Oral Microbiol Immunol* 2000;15(4):263-8.
16. Michelow IC, McCracken GH, Jr., Luckett PM, Krisher K. *Abiotrophia* spp. brain abscess in a child with Down's syndrome. *Pediatr Infect Dis J* 2000;19(8):760-3.
17. Leonard MK, Pox CP, Stephens DS. *Abiotrophia* species bacteremia and a mycotic aneurysm in an intravenous drug abuser. *N Engl J Med* 2001;344(3):233-4.
18. McCarthy L, Bottone E. Bacteremia and endocarditis caused by satelliting streptococci. *Am J Clin Pathol* 1974;61:585-91.
19. Barrios H, CM B. Conjunctivitis caused by a nutritionally variant streptococcus. *J Clin Microbiol* 1986;23:379-80.
20. Ormerod LD, Ruoff KL, Meisler DM, Wasson PJ, Kintner JC, Dunn SP, et al. Infectious crystalline keratopathy. Role of nutritionally variant streptococci and other bacterial factors. *Ophthalmology* 1991;98(2):159-69.
21. Heath CH, Bowen SF, McCarthy JS, Dwyer B. Vertebral osteomyelitis and discitis associated with *Abiotrophia adiacens* (nutritionally variant streptococcus) infection [letter]. *Aust NZ J Med* 1998;28(5):663.
22. Schlegel L, Merlet C, Laroche JM, Fremaux A, Geslin P. Iatrogenic meningitis due to *Abiotrophia defectiva* after myelography. *Clin Infect Dis* 1999;28(11):155-6.
23. Namdari H, Kintner K, Jackson BA, Namdari S, Hughes JL, Peairs RR, et al. *Abiotrophia* species as a cause of endophthalmitis following cataract extraction. *J Clin Microbiol* 1999;37(5):1564-6.
24. Keay L, Harmis N, Corrigan K, Sweeney D, Willcox M. Infiltrative keratitis associated with extended wear of hydrogel lenses and *Abiotrophia defectiva*. *Cornea* 2000;19(6):864-9.
25. Brouqui P, Raoult D. Endocarditis due to rare and fastidious bacteria. *Clin Microbiol Rev* 2001;14(1):177-207.
26. Johnson C, Tunkel A. Nutritionally variant (deficient) streptococci (*Abiotrophia*). In: Mandell G, Bennett J, Dolin R, editors. *Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases*. 5 ed. Philadelphia: Churchill Livingstone Inc; 2000. p. 2172-73.
27. Roberts RB, Krieger AG, Schiller NL, Gross KC. Viridans streptococcal endocarditis: the role of various species, including pyridoxal-dependent streptococci. *Rev Infect Dis* 1979;1(6):955-66.
28. Bouvet A. Human endocarditis due to nutritionally variant streptococci: *streptococcus adjacens* and *Streptococcus defectivus*. *Eur Heart J* 1995;16 Suppl B:24-7.
29. Roberts RB. Streptococcal endocarditis: The viridans and beta-hemolytic streptococci. In: Kaye D, editor. *Infective Endocarditis*. 2 ed. New York: Raven Press; 1992. p. 191-208.
30. Cooksey RC, Swenson JM. In vitro antimicrobial inhibition patterns of nutritionally variant streptococci. *Antimicrob Agents Chemother* 1979;16(4):514-8.
31. Okada Y, Kitada K, Takagaki M, Ito HO, Inoue M. Endocardial infectivity and binding to extracellular matrix proteins of oral *Abiotrophia* species. *FEMS Immunol Med Microbiol* 2000;27(3):257-61.
32. Gephart JF, Washington JA. Antimicrobial susceptibilities of nutritionally variant streptococci. *J Infect Dis* 1982;146(4):536-9.
33. Holloway Y, Dankert J. Penicillin tolerance in nutritionally variant streptococci. *Antimicrob Agents Chemother* 1982;22(6):1073-5.
34. Tuohy MJ, Procop GW, Washington JA. Antimicrobial susceptibility of *Abiotrophia adiacens* and *Abiotrophia defectiva*. *Diagn Microbiol Infect Dis* 2000;38(3):189-91.
35. Bouvet A, Cremieux AC, Contrepois A, Vallois JM, Lamesch C, Carbon C. Comparison of penicillin and vancomycin, individually and in combination with gentamicin and amikacin, in the treatment of experimental endocarditis induced by nutritionally variant streptococci. *Antimicrob Agents Chemother* 1985;28(5):607-11.
36. Henry NK, Wilson WR, Roberts RB, Acar JF, Geraci JE. Antimicrobial therapy of experimental endocarditis caused by nutritionally variant viridans group streptococci. *Antimicrob Agents Chemother* 1986;30(3):465-7.
37. Wilson WR, Karchmer AW, Dajani AS, Taubert KA, Bayer A, Kaye D, et al. Antibiotic treatment of adults with infective endocarditis due to streptococci, enterococci, staphylococci, and HACEK microorganisms. American Heart Association [see comments]. *Jama* 1995;274(21):1706-13.



Attention physicians!

Are you interested in learning how to make Medicare coding easier for you and your staff, and how to use computer technology to improve quality of care and decrease medical errors? If yes, please join us at our free coding seminar. You'll also earn CME credits at no cost!

Coding and Medical Errors Seminar
February 2, 2002
11:30 am – 5:00 pm
Radisson Waikiki Prince Kuhio Hotel

Seminar will feature two national speakers on this issue: M. Tray Dunaway, MD, FACS and Thomas Payne, MD, FACP. To register or receive more information, call 545-2550 or 1-800-524-6550 (toll free). Lunch and validated parking will be provided. There is no charge for this seminar.

Jointly sponsored by



and the Hawaii Consortium for Continuing Medical Education

Office of Cancer Communications

National Cancer Institute

Pap Tests
A healthy habit for life!

Pap tests can help find cervical cancer at an early stage — while it's still easier to cure.

Call the National Cancer Institute's
Cancer Information Service at
1-800-4-CANCER (1-800-422-6237).

Visit NCI's website at <http://www.nci.nih.gov>